<DOC>
	<DOCNO>NCT01817166</DOCNO>
	<brief_summary>The main objective study evaluate efficacy tolerance 2 year treatment cholecalciferol ( vitamin D3 ) patient clinically isolated syndrome high risk MS ( CIS ) .</brief_summary>
	<brief_title>Efficacy Cholecalciferol ( Vitamin D3 ) Delaying Diagnosis MS After Clinically Isolated Syndrome</brief_title>
	<detailed_description>The secondary objective study : A. evaluate clinical efficacy : delay conversion ; number relapses/episodes per year B. evaluate efficacy term resonance image parameter ( cerebral/spinal MRI ) C. evaluate efficacy term slow progression disability measure EDSS score subscores D. measure ass cognitive ability ( PASAT ) E. evaluate change quality life ( EQ5D questionnaire , SF36 , TLS-TLS-QoL10 COPING10 ) , fatigue questionnaire ( FSMC ) anxiety / depression questionnaire ( HADS ) F. evaluate treatment tolerance G. correlate change clinical image parameter evolution serum level 25 ( OH ) D2 25 ( OH ) D3 H. establish biobank DNA RNA patient study conduct analysis gene polymorphism involve metabolism vitamin D HLA system base increased level vitamin D supplementation I. establish biobank CSF , plasma , blood cell , serum RNA sample patient select center research prognostic biomarkers conversion J. establish biobank consist plasma tube collect determination 25-hydroxy-vitamin D K. Estimate rate discordance conversion decision make study neurologist result MRI re-interpretation perform end study well proportion patient identify posteriori erroneously include accord centralize reading .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>The patient must give his/her inform sign consent The patient must insure beneficiary health insurance plan The patient available 24 month followup The patient classic CIS past 90 day Reference cerebromedullary MRI schedule within 90 day begin symptom With MRI ( cerebro Â± medullary ) show demyelination accord spatial spread criterion Swanton ( 2006 ) : At least 1 lesion least 2 4 follow territory : ( 1 ) Periventricular ; ( 2 ) Juxtacortical ; ( 3 ) Subtentorial ; ( 4 ) Medullary No suspect pathology Vitamin D level blood le 100 nmol / l preinclusion visit Women childbearing potential must use effective contraception duration study . A effective contraceptive method define method result low failure rate ( say less 1 % per year ) use consistently correctly , implant , injectables , combine oral contraceptive , IUDs , sexual abstinence , partner vasectomy . Randomisation stratification criterion : The patient also also meet temporal dissemination criterion define accord McDonald criterion 2010 ( Polman et al. , 2011 ) , condition currently sufficient prescribe background treatment : Simultaneous presence least one asymptomatic lesion take contrast least one asymptomatic lesion take contrast injection gadolinium The patient participate another study ( criterion apply POLAR study ( RCB 2011A0126932 ) ; patient include study may simultaneously participate POLAR study ) The patient exclusion period determine previous study The patient judicial protection , tutorship curatorship The patient refuse sign consent It impossible correctly inform patient The patient pregnant , parturient , breastfeed Major medical psychiatric illness , accord investigator , would result patient run unnecessary risk could affect compliance study protocol Vitamin D insufficiency link currently active digestive general disease ( celiac disease , inflammatory bowel disease , intestinal bypass , short bowel syndrome , cirrhosis , nephrotic syndrome , hyperthyroidism , rickets , hypoparathyroidism , cancer , granulomatous disease lymphomas ) Moderate severe renal insufficiency ( creatinine clearance le 60 ml / min ) Epilepsy adequately control treatment Any illness require chronic treatment corticosteroid Patient osteoporosis history osteopenia Pathology require calcium intake great 1 gram per day Current past history hypercalcemia Medications affect metabolism vitamin D corticosteroid ; e.g . anticonvulsant [ phenobarbital , primidone , phenytoin ] rifampicin , isoniazid , ketoconazole , 5FU leucovorin , thiazide diuretic . Situations accompany increased vulnerability hypercalcemia , e.g . arrhythmia know heart disease , treatment digitalis , subject nephrolithiasis . Contraindications vitamin D3 mention documentation UVEDOSE Known hypersensitivity gadolinium / know inability undergo MRI ( pacemaker , osteosynthesis material , intraocular metal splinter , etc ... . ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>56 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>cholecalciferol</keyword>
	<keyword>vitamin D</keyword>
	<keyword>immune disease</keyword>
	<keyword>clinically isolated syndrome</keyword>
</DOC>